BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Monday, July 14, 2025
Home » Authors » Anette Breindl

Anette Breindl

Articles

ARTICLES

Images showing the green fluorescence signals in different body parts of the live-birth chimeric monkey.
Drug Design, Drug Delivery & Technologies

1st chimeric monkey born with large embryonic stem cell contribution

Nov. 14, 2023
By Anette Breindl
Investigators at the Chinese Academy of Sciences have generated a chimeric monkey by injecting an embryonic stem cell into the morula, which is an extremely early embryo consisting of 16 to 32 cells. The animal survived for only 10 days, and it is not the first live birth of a chimeric primate. But it is the first such chimera with contributions from an embryonic stem cell, and that stem cell contributed a far higher proportion of cells in the newborn than have been achieved in previous attempts at creating chimeras.
Read More
Dorsal striatum and its neurons in Huntington's disease
Neurology/Psychiatric

SfN 2023: Lessons from Huntington’s successes, and failures

Nov. 13, 2023
By Anette Breindl
The gene for Huntington’s disease “was cloned in 1993, and everyone thought there was going to be a treatment right around the corner,” Sarah Tabrizi told the audience at the 2023 Annual Meeting of the Society for Neuroscience. Then, “it took 25 years for the first trial targeting the Huntington gene.”
Read More
Images showing the green fluorescence signals in different body parts of the live-birth chimeric monkey.
Drug Design, Drug Delivery & Technologies

1st chimeric monkey born with large embryonic stem cell contribution

Nov. 9, 2023
By Anette Breindl
Investigators at the Chinese Academy of Sciences have generated a chimeric monkey by injecting an embryonic stem cell into the morula, which is an extremely early embryo consisting of 16 to 32 cells. The animal survived for only 10 days, and it is not the first live birth of a chimeric primate. But it is the first such chimera with contributions from an embryonic stem cell, and that stem cell contributed a far higher proportion of cells in the newborn than have been achieved in previous attempts at creating chimeras.
Read More
Chronophoto Parkinsons Disease Patient

Spinal cord implant restores skilled walking in Parkinson’s patient

Nov. 6, 2023
By Anette Breindl
Electrical stimulation of the spinal cord has restored the ability to walk normally to a patient whose chronic Parkinson’s disease (PD) had led to severe motor deficits, researchers reported in the Nov. 6, 2023, online issue of Nature Medicine.
Read More
Vial and syringe with DNA

In HIV, gene therapy could be alternative path to functional cure

Oct. 27, 2023
By Anette Breindl
At the 30th Annual Congress of the European Society for Gene and Cell Therapy in Brussels this week, researchers presented both preclinical and clinical strategies for applying gene therapy to a functional HIV cure. At a Wednesday session on Infectious Diseases & Vaccines, Alessio Nahmad, of Tabby Therapeutics Ltd., described using B cells edited to express broadly neutralizing antibodies (bnAbs) 3BNC117 to deliver high titers of antibodies in mice.
Read More
Vial and syringe with DNA
Drug Design, Drug Delivery & Technologies

In HIV, gene therapy could be alternative path to functional cure

Oct. 26, 2023
By Anette Breindl
At the 30th Annual Congress of the European Society for Gene and Cell Therapy in Brussels this week, researchers presented both preclinical and clinical strategies for applying gene therapy to a functional HIV cure. At a Wednesday session on Infectious Diseases & Vaccines, Alessio Nahmad, of Tabby Therapeutics Ltd., described using B cells edited to express broadly neutralizing antibodies (bnAbs) 3BNC117 to deliver high titers of antibodies in mice.
Read More
CRISPR-edited kidney under microscope
Immune

Most-edited-ever donor genomes lead to 2-year survival in porcine-to-primate kidney transplants

Oct. 11, 2023
By Anette Breindl and Mar de Miguel
Scientists at Egenesis Inc. have transplanted kidneys from genome-edited pigs into cynomolgus monkeys that remained functional for long periods after transplantation. The monkeys, whose own kidneys were removed during the surgery, survived for a median of 176 days after receiving one pig kidney. Maximal survival was just over 2 years. The data were published today in Nature. Egenesis CEO Mike Curtis told reporters that the study has achieved the longest survival to date “using clinically translatable immunosuppression … longer survival has been achieved using really aggressive immunosuppression that really isn’t clinically translatable.”
Read More
CRISPR-edited kidney under microscope
Immune

Most-edited-ever donor genomes lead to 2-year survival in porcine-to-primate kidney transplants

Oct. 11, 2023
By Anette Breindl and Mar de Miguel
Scientists at Egenesis Inc. have transplanted kidneys from genome-edited pigs into cynomolgus monkeys that remained functional for long periods after transplantation. The monkeys, whose own kidneys were removed during the surgery, survived for a median of 176 days after receiving one pig kidney. Maximal survival was just over 2 years. The data were published today in Nature. Egenesis CEO Mike Curtis told reporters that the study has achieved the longest survival to date “using clinically translatable immunosuppression … longer survival has been achieved using really aggressive immunosuppression that really isn’t clinically translatable.”
Read More
AI generated illustration of a brain on fire
Neurology/Psychiatric

ECNP 2023: Look for antibodies in idiopathic psychoses? First, maybe better tests

Oct. 10, 2023
By Anette Breindl
For individuals who develop an unexpected psychosis, there is something to be said for testing them for autoimmune antibodies. And something against. At the 36th Congress of the European College of Neuropsychopharmacology (ECNP) this week, the topic was worth a controversy session, where speakers presented the pros and cons of the approach. Currently used tests have a specificity of 99%. But as Ester Coutinho, consultant neurologist at the University of Coimbra, pointed out, the validity of diagnostic tests depends on the prevalence of the disorder one is looking for as well. Coutinho estimated that autoimmune psychoses account for 1% of psychoses overall.
Read More
Woman  in military clothing talking with psychologist
Neurology/Psychiatric

ECNP 2023: Boosting fear unlearning is one avenue toward treating PTSD

Oct. 9, 2023
By Anette Breindl
For most psychiatric illnesses, the precipitating event is mysterious. Many conditions are thought to result from a mix of genetic risk and environmental factors, but the specific trigger remains unknown. In post-traumatic stress disorder (PTSD), the environmental trigger is usually clear. In many cases, it is all the affected individuals can think about. “Intrusive reliving” of the triggering situation is one of the core features of PTSD.
Read More
View All Articles by Anette Breindl

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for July 11, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for July 11, 2025.
  • Scientific figure illustrating astrocytes and neuron synapse

    Glia 2025: Microglial crosstalk could be early Alzheimer’s targeting opportunity

    BioWorld
    “Loss of synapses and dysfunctional synapses in a region-specific way is important in Alzheimer’s. It’s actually the strongest correlate of cognitive decline, far...
  • New oral BRD4 inhibitor blocks pathogenic expansion of epithelial progenitors in IPF models

    BioWorld Science
    Idiopathic pulmonary fibrosis (IPF) is a progressive and fatal lung disease with limited treatment options. IPF is thought to result from repeated microinjuries...
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for July 8, 2025
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing